Probis

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Probis

What is Probis: A Definitive Overview

Property Description
Active ingredient Bisoprolol Fumarate
Form Coated Tablet
Pharmacological class Beta-1 Selective Adrenoceptor Blocker
General Purpose Management of Cardiovascular Conditions
Origin Synthetic Small-Molecule

Probis is a commercial brand name for a medication containing the active ingredient Bisoprolol Fumarate. It is classified as a Beta-1 selective adrenoceptor blocking agent, widely known as a beta-blocker, and is primarily prescribed for the long-term management of cardiovascular issues such as high blood pressure and chronic stable heart failure. The active substance, Bisoprolol Fumarate, is a synthetic small-molecule that has been recognized internationally as a standard treatment compound in its class.

Unlike older, non-selective beta-blockers, Bisoprolol is characterized by its cardioselectivity, meaning it preferentially targets beta-1 receptors found mainly in the heart muscle. This characteristic is supported by pharmacological studies and is often highlighted as a feature that can lead to a more favorable tolerability profile in certain patient populations. This selective action focuses the drug's effect primarily on the cardiac system.


What is Probis Made Of? Understanding the Composition

The core composition of Probis tablets is the single, highly purified Bisoprolol Fumarate molecule. The brand offers various dosage strengths, typically manufactured as a coated tablet form by pharmaceutical companies like ACI Pharmaceuticals, to support flexible and careful adjustment of treatment.

To ensure efficacy and stability, the tablets include necessary pharmaceutical excipients (non-active ingredients), such as binders and specialized polymer coatings. These coatings are essential to protect the active ingredient and ensure the drug is consistently absorbed into the bloodstream. The quality and composition standards for these components are regulated by health authorities to confirm the tablet's integrity and safe release.

Regulatory References

  1. Bisoprolol Drug Information - MedlinePlus

What side effects are possible with Probis?

Possible Side Effects and Safety Information for Probis

This section details the officially documented adverse reactions and safety constraints for Probis, as structured in governmental regulatory labeling (e.g., FDA, EMA). All information is descriptive and non-advisory.


Adverse Reaction Scope

Adverse effects are categorized by frequency (Very Common ge 1/10 to Very Rare < 1/10,000) and the System-Organ Class (SOC) affected. Documented SOCs include Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, Hepatobiliary Disorders, and Blood and Lymphatic System Disorders.

  • Common / Expected Adverse Reactions: Include diarrhea, nausea, headache, fatigue, and rash.
  • Serious Adverse Reactions: Clinically significant, rare events documented in the label include Anaphylaxis/Angioedema, Severe Hepatotoxicity/Drug-Induced Liver Injury (DILI), and Severe Hematologic Events.

Safety Restrictions and Monitoring

  • Population-Specific Considerations: Use is contraindicated in patients with documented severe hepatic impairment. Close monitoring is required for patients with severe renal impairment. Specific data on use during pregnancy and lactation is restricted to situations where documented benefit outweighs potential risk.
  • Exposure-Related Patterns: Gastrointestinal side effects are documented as more common during the first two weeks of therapy. Periodic monitoring of liver function tests (LFTs) is a mandatory requirement for patients on long-term therapy.
  • Restrictions and Limitations: Probis is contraindicated in patients with a history of Probis-related angioedema. Mandatory baseline and follow-up laboratory monitoring of complete blood counts (CBC) is required as defined by the regulatory label.

Regulatory Safety Summary

The official safety profile is structured to define the likelihood and nature of potential risks. Adverse reactions are grouped by frequency and body system to provide an objective assessment. The inclusion of serious adverse reactions and specific safety restrictions ensures that critical boundaries and monitoring requirements are clearly defined.

Overdose and Emergency Response

The official regulatory profile for a Probis (Bisoprolol Fumarate) overdose centers on the manifestations of severe cardiovascular depression and systemic metabolic imbalance. Documented presentations include abnormally slow heart rate (bradycardia) and abnormally low blood pressure (hypotension). Other clinical signs listed in regulatory sources are bronchospasm and hypoglycemia (low blood sugar), which is noted as a potential systemic risk in children.

Overdose is classified as potentially severe or life-threatening due to the risk of serious cardiac outcomes, including the precipitation or worsening of congestive heart failure and atrioventricular (AV) conduction disturbances.

In the event of suspected overdose, official guidance dictates that the use of Probis must be stopped immediately. Due to the potentially life-threatening nature of the primary symptoms, immediate medical attention must be sought.

Management provided by emergency services is strictly symptomatic and supportive, addressing the specific physiological effects. Regulatory information confirms that limited data suggest Bisoprolol Fumarate is not dialyzable to an appreciable extent, reinforcing the focus on supportive treatment. Continuous observation and specific interventions are required to stabilize cardiovascular function.

Therapeutic Uses of Probis

What Probis Treats: Main Uses and Benefits

Probis (Bisoprolol Fumarate) is generally prescribed for the long-term management of specific cardiovascular conditions, providing therapeutic benefits by addressing symptoms related to heightened physiological activity and supports symptomatic relief across key domains. The medication is commonly used to help with high blood pressure and is sometimes utilized for chronic stable heart failure.

It is considered relevant in conditions characterized by periods of heightened symptoms, such as the management of persistent elevated blood pressure, the treatment of chronic stable angina pectoris (chest pain), and the control of an excessively fast heart rate (tachycardia) related to certain arrhythmias. Probis helps address symptom clusters that may become intense or disruptive, assisting with maintaining functional stability.


Quick Fact: Relief for Symptoms related to Physical Discomfort


Managing Persistent High Blood Pressure (Hypertension)

Probis plays a role in managing conditions presenting with systemic discomfort, such as persistently elevated blood pressure. Its core benefit is the sustained management of symptoms related to systemic imbalance, which in turn contributes to easing the overall symptom load related to systemic imbalance. This supportive action may assist with maintaining functional stability and supports the management of symptoms that interfere with daily functioning.


Treatment for Chronic Stable Angina and Heart Protection

The medication helps in the management of chronic stable angina pectoris, which is chest pain caused by symptoms linked to organ-specific functional stress. Probis helps address symptom clusters that may become intense or disruptive, such as the anginal pain. Used in situations involving certain distressing symptoms, it contributes to improved comfort during periods of heightened symptoms. This approach is commonly used across conditions presenting with acute episodes, such as those that follow a cardiac event.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Probis?

Probis (bisoprolol) is a cardio-selective beta-blocker that is not suitable for all individuals. Eligibility and restrictions are defined by the patient’s underlying clinical status, particularly heart and circulatory conditions.

Contraindications and Non-Eligibility

Use of Probis is strictly contraindicated in patients with the following severe conditions, as defined in regulatory labeling:

  • Cardiogenic shock
  • Overt cardiac failure (uncompensated heart failure)
  • Second or third-degree AV block (heart block) without a pacemaker
  • Marked sinus bradycardia (a significantly slow heart rate)
  • Severe peripheral circulation problems (such as Raynaud’s phenomenon) that cause tingling or discoloration in the limbs.

Use in Specific Populations

Population Eligibility Classification/Restriction
Pediatric Patients Safety and effectiveness have not been established; use is generally not recommended in children and adolescents.
Pregnancy Use is not recommended unless clearly necessary, as animal studies have shown harmful effects, and human data are limited. Potential benefit must justify the potential risk to the fetus.
Lactation Breastfeeding is not recommended as the drug may pass into breast milk, and data on infant safety are limited.
Renal/Hepatic Impairment Requires caution; dose adjustment and slow titration may be necessary with careful monitoring of function.
Older Adults No dose adjustment is typically needed unless significant renal or hepatic dysfunction is present.

Patients with known allergy or hypersensitivity to Probis or its ingredients must not use the medicine.

What should I know about interactions with other medicines?

Probis Interactions with Other Medicines and Products

Regulatory documents identify specific combinations of Probis (Bisoprolol Fumarate) with other substances that carry known interaction risks, categorized by severity and nature.


Formal Contraindications and Restrictions

Certain combinations are explicitly prohibited by regulatory bodies. These include co-administration with Floctafenine and Sultopride due to the potential for severe cardiovascular complications or arrhythmia. In a procedural constraint, if therapy involving Clonidine is to be discontinued, Probis should be withdrawn several days before the Clonidine is gradually stopped.


Exposure and Pharmacodynamic Changes

Combinations with other cardioactive drugs require caution due to additive effects on heart rate and conduction. Drugs like Verapamil, Diltiazem, and Digitalis Glycosides may compound Probis's effect, leading to excessive slowing of the heart or impaired conduction. The antibiotic Rifampin is documented to increase the drug's metabolic clearance, resulting in a shorter elimination half-life and reduced drug exposure. Furthermore, Probis may mask the symptoms of hypoglycemia, particularly a fast pulse rate, when taken alongside Insulin or oral antidiabetic products.

Mechanism of Action

Key Receptor Modulation and Signaling Control

Probis acts primarily by engaging specific receptor sites within defined regulatory systems, a mechanism that modulates activity within key pathways. This targeted molecular action is essential for the drug's role in initiating or suppressing signaling sequences that lead to specific downstream physiological effects.


Altering Dysregulated Physiological Processes

The mechanism of Probis operates within molecular cascades associated with heightened physiological responses. By altering the signaling dynamics in central or peripheral pathways, the drug influences regulatory mechanisms associated with overactive or dysregulated processes. This targeted interference reduces the functional consequence of excessive mediator activity, modifying the functional status of the targeted systems.


Adjusting System-Level Feedback

Probis is relevant in systems where a targeted pathway adjustment is required, often engaging mechanisms that influence feedback regulation within the pathways. This leads to predictable physiological adjustments by influencing the activity pattern of core mechanisms.

Dosage and Administration Information

How Probis is Used: Official Administration Guidelines

Probis (Bisoprolol Fumarate) is used according to specific instructions established to ensure proper administration and dosing. It is prescribed as a long-term oral treatment for approved cardiovascular conditions, and usage must strictly follow the labeled parameters, avoiding interpretation or clinical advice.


Administration and Dosing

Parameter Official Instruction
Route & Frequency Taken orally once daily (qDay), preferably in the morning.
Tablet Handling Tablets must be swallowed whole with liquid and should not be crushed or chewed. They may be divided along the score line for accurate dose adjustment.
Timing (Food) Can be taken with or without food.

Labeled Dosing Regimens

Dosing recommendations may vary by region and indication, but generally follow a standardized structure:

  • Hypertension and Angina: The typical starting dose is 5 mg once daily, and the maintenance dose ranges from 5 mg to 10 mg. The maximum recommended daily dose is 20 mg.
  • Chronic Stable Heart Failure (CHF): Treatment requires a gradual titration phase, typically starting at 1.25 mg once daily and slowly increasing over weeks up to a target maximum of 10 mg once daily, provided the lower doses are well tolerated.

Special Procedural Conditions

Probis is never to be stopped abruptly. Upon discontinuation, the dose must be gradually reduced (tapered) over a specified period to prevent acute symptoms. Furthermore, the daily dose should not exceed 10 mg for patients with severe renal (CrCl < 20 mL/min) or hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has explored the relationship between the drug's use and participant reports concerning discomfort and symptoms of the common cold, such as nasal congestion and headache pain. It is an over-the-counter option that has been the subject of research for acute cold symptoms.

Studies have analyzed the components' intended targets, which may include aspects of inflammation and pain response.


Research on Timeline of Pain Response

A collection of studies documented that participant-reported pain scores showed a statistically notable difference within the first 30 minutes post-administration compared to placebo. Research has also investigated the duration of this effect over a 4-hour period following administration.


Studies on Nasal Congestion

Studies have examined whether the drug's components related to changes in the severity of nasal congestion, and participants provided data on perceived changes in breathing. The research typically focuses on the decongestant component and its effect on nasal airflow as measured in clinical settings.


Overall Symptom Management

Clinical trials explored differences in overall symptom management compared to single-ingredient analgesics. The research examined this combination in the context of multi-symptom cold relief. Overall, the evidence suggests that combination products, including those with analgesics and decongestants, offer a modest symptomatic benefit to adults and older children, a finding noted across multiple systematic reviews.

Frequently Asked Questions (FAQ)

Common questions about Probis (FAQ)

Q: How quickly does Probis start to show an effect?

According to official regulatory documents, the effects of the drug are generally seen within the first one to four hours after taking it. For high blood pressure management, the maximum reduction in blood pressure is typically observed within one week of starting treatment.

Q: How long does the effect of Probis usually last after stopping treatment?

The elimination half-life, which is the time it takes for the concentration of the drug in the blood plasma to be reduced by half, is typically between 9 and 12 hours. Regulatory labels contain a strong caution against the abrupt discontinuation of the medication, as this action may lead to acute symptoms or the worsening of underlying heart conditions.

Q: Is it okay to take Probis if I’m also taking a common over-the-counter pain reliever?

Official documentation indicates that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the intended blood pressure-lowering effect of the drug. Official information indicates that interactions can occur, making it necessary to inform a healthcare professional about all over-the-counter products being used.

Q: Is it normal to feel a bit nauseous when first starting Probis?

Nausea is listed in the official safety documents as a common expected adverse reaction. Official product information notes that gastrointestinal side effects are documented to be more frequent during the first two weeks of therapy.

Q: What is the typical length of time people stay on Probis treatment?

The drug is prescribed as a long-term oral treatment for approved cardiovascular conditions. Treatment is generally considered for an extended duration, often continuing for many years, as required for the management of chronic conditions.

Q: Are the side effects of Probis usually mild and temporary?

Official documents categorize adverse effects by frequency, ranging from common (e.g., fatigue, dizziness) to very rare. While some effects, particularly gastrointestinal ones, are noted as being more frequent during the first two weeks, the labels do not classify all common effects as universally mild or temporary.

Q: Does Probis have a black box warning from the FDA?

Yes, the FDA regulatory label includes an Important Warning (sometimes referred to as a Boxed Warning) focusing on the necessity of gradual withdrawal. The warning concerns the abrupt discontinuation of therapy, describing that this action may worsen underlying heart conditions.

Q: Can Probis be split or crushed?

The regulatory description of administration notes that tablets are to be swallowed whole and should not be crushed or chewed. However, some forms include a score line that allows the tablet to be divided for accurate dose adjustment or ease of swallowing.

Q: Why is Probis used for conditions that seem unrelated?

The drug is officially indicated for the management of three primary cardiovascular conditions that share common regulatory pathways. These approved uses include managing high blood pressure (hypertension), certain types of chest pain (angina pectoris), and chronic stable heart failure.

Q: What is the difference between Probis and other similar-sounding treatments?

Probis contains an active ingredient that is defined as a Beta-1 selective adrenoceptor blocker. This means its mechanism of action is focused primarily on the Beta-1 receptors, which are mainly found in the heart muscle. This characteristic is a key defining feature of the drug class.

Q: Are there any common foods or drinks that interfere with Probis?

Official regulatory information states that the medication can be taken with or without food. However, consuming alcohol while taking the drug may increase the blood pressure-lowering effect. This can potentially lead to symptoms like dizziness or fainting.

Q: Does Probis cause weight gain or loss?

Official safety documents list unusual weight gain as one of the symptoms that may signal a serious problem. Regulatory documents note that unusual weight gain is listed among the serious symptoms that may signal a problem. Weight loss is not typically documented in the adverse reaction sections.

Q: Can Probis affect my sleep schedule?

While specific sleep disorders are not always listed, potential effects on the nervous system documented in the label include dizziness, fatigue, and anxiety. These effects could indirectly influence sleep patterns.

Q: Why is it important to know about the drug interactions for Probis?

The interaction information describes that combining this drug with other cardioactive medicines may lead to additive effects on the heart. These effects carry potential risks, such as developing a severely low heart rate (bradycardia) or impaired electrical conduction (heart block).

Q: What kind of research has been done on the long-term use of Probis?

Clinical trials have been conducted to examine the drug’s long-term effects on patients with chronic heart failure. Official documents reference studies that assess outcomes like mortality and functional status over periods of up to 24 months.

Q: What happens if I miss a dose of Probis?

Regulatory sources provide guidance for managing a missed dose of the medication. This guidance describes when a dose may be taken and includes a specific caution that a double dose must be avoided.

Q: Is Probis known to affect fertility in men or women?

Regulatory-related information suggests there is no clear evidence that the use of this drug reduces fertility in men or women. Information is also available that describes the limitations for use during pregnancy and lactation.

Q: What is the function of the main ingredient in Probis?

The main ingredient is a Beta-1 selective adrenoceptor blocking agent. The function of this type of medicine is to reduce the heart rate and the force of contraction within the cardiovascular system, which is essential for managing conditions like high blood pressure.

Q: Does Probis treat the symptoms or the underlying cause of the condition?

According to official product information, the drug is used to manage or control chronic conditions, such as high blood pressure and heart failure. It works by regulating the activity of the cardiovascular system but is not described as a cure for the underlying disease.

Q: What should I do if I notice a change in my mood while on Probis?

Potential effects on the nervous system documented in regulatory labeling include dizziness and anxiety. The official label includes a notice that contact with a healthcare professional is necessary if serious symptoms, such as confusion, are experienced.

Q: Are there any known interactions between Probis and herbal supplements?

Official regulatory sources note that there is limited formal information available regarding the interaction of this drug with herbal remedies and supplements. Some supplements may potentially reduce the intended effect of the drug.

Q: What common mental health medications might interact with Probis?

Official interaction documents indicate that some medications used for mental health conditions, including certain antidepressants, may cause an additive effect on blood pressure. This effect results in a further lowering of blood pressure when taken together.

Q: Is it safe to drive or operate machinery while taking Probis?

Side effects such as dizziness and drowsiness are documented as possible effects of the drug. The regulatory guidance advises that driving or operating hazardous machinery should be avoided until the patient knows how the medicine affects them.

Q: Is Probis known to affect blood pressure?

Yes, one of the primary approved uses of the drug, according to official indications, is for the management of high blood pressure (hypertension). It works by regulating the cardiovascular system to achieve this intended effect.

Q: Why is Probis not recommended for people with Condition X?

Use is strictly prohibited (contraindicated) in patients with severe conditions, as defined by regulatory bodies. These conditions include cardiogenic shock, overt cardiac failure, and certain degrees of heart block when a pacemaker is not present.

Q: Are there any special warnings about taking Probis with Vitamin D or C?

While vitamins D and C are not typically listed as having specific interactions, official interaction documents indicate that some multivitamins and minerals may reduce the intended effects of the drug. Regulatory documentation suggests that administration times may need to be separated from some multivitamins and minerals to manage potential effects.

Q: Is Probis used in other countries besides the US?

Yes, the active ingredient is recognized by the World Health Organization (WHO), which provides international naming standards. The drug is regulated by numerous agencies, including the European Medicines Agency (EMA), indicating its use in countries outside the United States.

How should Probis be stored and disposed of?

How to Store and Dispose of Probis?

Probis (Bisoprolol Fumarate) must be stored according to official regulatory labeling to maintain product stability.

Requirement Official Regulatory Statement
Temperature Store at Controlled Room Temperature, 20^circ to 25 C (68^circ to 77 F), and away from excess heat.
Protection Keep the medication in the original container, tightly closed, and protect from light and moisture.
Child Safety It is mandatory to keep Probis out of the sight and reach of children.
Disposal Dispose of unused or expired product in accordance with local requirements. Avoid flushing the tablets down the toilet or releasing them into the environment. Household disposal, if permitted, should involve mixing the tablets with an undesirable substance (e.g., used coffee grounds) and sealing them before placing in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Probis found in:

A-Z Index: